Blog Read the latest perspectives from our team of subject matter experts and others Trials, Data, Diversity – H1’s Top 5 Diagnoses (Predictions) for Biotech and Pharma in 2024How will AI impact clinical trials? Will FDA legislation improve diversity? What platforms will key opinion leaders adopt? Every year, we take a look at annual predictions to help life… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Diversity & Inclusion Drug Development Global Impact HCP Volunteers KOL Engagement Provider Data Research Post Industries:Commercialization Global Impact Payors Pharmaceutical & Biotechnology Provider Data Research CommercializationDiversity & InclusionDrug DevelopmentKOL EngagementProvider DataResearchNew Look, Same Commitment!I’m excited to officially unveil the new branding and website our team has been working on for several months. This new branding comes with much thought and consideration, and reflects… Continue reading → Read the articleno Artificial IntelligenceKOL EngagementAI and the MSL Evolution: What Time Has Taught UsI recently had the chance to deliver the keynote address at the 2022 MSL Society Conference in Las Vegas. It’s been a transformative year for pharma and life sciences, specifically… Continue reading → Read the article CommercializationDiversity & InclusionDrug DevelopmentKOL EngagementProvider DataResearchTimmy Awards Announces H1 as 2022 Tech for Good FinalistThe 8th Annual Timmy Awards run by Tech in Motion celebrates leaders in tech, recognizing the top workplaces for tech professionals across North America. We are thrilled to announce that H1 is… Continue reading → Read the article KOL EngagementGoing with the Digital FlowEven now: two and a half years later, the COVID-19 pandemic continues to have a substantial impact on the activities of Medical Science Liaisons (MSLs), including access to Key… Continue reading → Read the article Diversity & InclusionDrug DevelopmentThe ABCs (and Ds) of Clinical Trial DiversityWhen the FDA mandated guidelines earlier this year for broader clinical trial diversity and inclusion, it brought a long-standing challenge in pharma and life sciences into the spotlight. Here, Alexandra… Continue reading → Read the articleno Diversity & InclusionDrug DevelopmentKOL EngagementA New Reflection on Pharma, Research, and Patient CarePharma has long existed in elevated, prestigious academic institutions: ivory towers of reputable and revered centers of excellence famous for disseminating the latest in clinical research and medical breakthroughs.… Continue reading → Read the article«‹567891011›»